With $1.4B Emisphere buy, Novo gets delivery tech used in Rybelsus

With its takeout of Emisphere, Novo will gain control of an oral drug delivery technology it has already used in a product crucial to its future, while also buying out that drug’s royalty stream.

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) will pay nearly $1.4 billion to acquire New Jersey-based Emisphere Technologies Inc. (Pink:EMIS), whose Eligen delivery platform Novo used in Rybelsus semaglutide, the first oral GLP-1R agonist approved to treat Type II diabetes...